Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previous
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... million milestone payment from Biogen Idec related to advancing ... in infants with spinal muscular atrophy (SMA).  ... Rx, is a randomized, double-blind, sham-procedure controlled thirteen ... The study will evaluate the efficacy and safety of ...
(Date:3/5/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for the fourth quarter and ... , Net Revenues Increased 21.3% Year Over Year ... Grew 17.7% Year Over Year to $140.5 Million ...
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... proof of concept for company,s first-in-class SERM designed ... with hormone therapy--CAMBRIDGE, Mass., March 24 Radius ... has been dosed in the company,s proof-of-concept Phase ... receptor modulator (SERM) undergoing clinical evaluation for treatment ...
... Own Power in Health Care Decisions?CHARLOTTE, N.C., March 24 ... vibrant and healthy life at any age, or to ... & Symposium may have the answers right in your ... year,s premier health and wellness event in the queen ...
Cached Medicine Technology:Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 2Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 3Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Ticket Down is ... Portland, Oregon at the Moda Center. After being ... Garth Brooks is showing no signs of letting up on ... country legend and his wife, Trisha Yearwood, to venues around ... be bringing their critically acclaimed tour to the Moda Center ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance ... hired two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D ... Grace Pavlath, Ph.D, who joined MDA late last year ... together will lead MDA as it accelerates new front-line ... types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... US Sports Football Camps expands its network ... non-contact specialty camps and one contact football camp. The ... located at Bowie State University and Riverdale Baptist School. ... speed and strength of football athletes. The contact football ... Graves, former quarterback in the Canadian Football League, as ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... GA (PRWEB) March 06, 2015 ... announced the release of a Clostridium Difficile (C ... providers. The C Diff use case is the ... that span hospital acquired infections, chronic conditions, and ... platform, the C Diff solution flags at risk ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Ala., May 27 Leading fitness social network and tracking ... name to DailyBurn , effective immediately.In just ... community of more than 125,000 members, who have, depending on ... gained an average of 5.75 lbs of muscle using DailyBurn,s ...
... - New national survey reveals insights on treatment ... treatmentROCKLAND, Mass. and NEW YORK, May 27 ... with EMD Serono, today released findings from a ... Outlook on Emerging Therapies" in conjunction with the ...
... Practical Insights on Physician Engagement, Career SuccessSCOTTSDALE, Ariz., ... Corporation, whose Fusionfx solution suite aggregates ... single, clinically relevant views of patient information, today ... papers documenting the increasing involvement of healthcare chief ...
... at "A Chocolat au Vin Affair," St. Jude Inaugural Gala with ... 2009, 8:00pm, New York City. , ... (PRWEB) May ... the fight against childhood cancer by supporting St. Jude Children,s Research ...
... ), a comprehensive New Jersey anti-poverty charity, is experiencing an increase ... individual gifts -- Eva,s Village, Paterson, New Jersey, seeks additional funding ... ... (PRWEB) May 27, 2009 -- Eva,s Village describes an increase ...
... reducing their healthcare and insurance expenses during a hard-hitting ... ... Net implemented an across-the-board increase in California Medicare supplement insurance plan ... new ways to maximize healthcare dollars and minimize expenses says MedicareSupplementPlans.com., ...
Cached Medicine News:Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 2Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 3Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 4Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 5Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 2Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 3Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 4Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 2Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 3Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 4Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 5Health News:Seniors Seek to Reduce Healthcare Costs as Premiums Increase Says MedicareSupplementPlans.com 2
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... a revolutionary scientific breakthrough for controlling unsightly ... Cream permits you to spot reduce in ... can rid yourself of those unwanted lumps ... to your thigh, waist, tummy, or chin ...
... G5 Contour is a non-invasive massage ... nodes and the circulatory system. Extraordinary ... G5 Directional-Stroking action, which combines vertical ... and comfortable percussion, gyratory massage, deep ...
The Ritter 204 Manual Exam Table. Featuring the latest in design, comfort and functionality in a manual exam table, it truly offers efficient patient care....
Medicine Products: